Market Research Logo

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

Summary

Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism-neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson’s market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.GlobalData estimates that drug sales for PD in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothena’s PRX-002and Acorda’s CVT-301, which both address some of the unmet needs in the market.Key Questions Answered

  • What are the key PD treatments in 2016?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?


  • Scope
    • Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
    • Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.
    • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
    • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.
    • Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
    Reasons to buy

    The report will enable you to -
    • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
    • Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
    • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
    • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
    • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
    • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


    1 Table of Contents
    1.1 List of Tables
    1.2 List of Figures
    2 Parkinson’s Disease: Executive Summary
    2.1 Parkinson’s Market Forecast to Reach $8.8B by 2026
    2.2 New Players Expected to Establish Themselves in the Forecast Period as Late-Stage Pipeline Assets Launched
    2.3 Disease-Modifying Agents and Late-Stage Complications the Largest Unmet Needs in the PD Market
    2.4 Treatments for Late-Stage Complications, Including Dyskinesia and Psychosis, Provide Companies with European and Japanese Opportunity
    2.5 Biologics and Reformulations Expected to Drive Growth Pipeline
    2.6 What Do Physicians Think?
    3 Introduction
    3.1 Catalyst
    3.2 Related Reports
    3.3 Upcoming Related Reports
    4 Disease Overview
    4.1 Etiology
    4.1.1 Overview
    4.1.2 Aging
    4.1.3 Environmental Factors
    4.1.4 Genetic Factors
    4.2 Pathophysiology
    4.2.1 Overview
    4.2.2 Mechanisms of Cell Death
    5 Epidemiology
    5.1 Disease Background
    5.2 Risk Factors and Comorbidities
    5.3 Global and Historical Trends
    5.3.1 US
    5.3.2 5EU
    5.3.3 Japan
    5.4 Forecast Methodology
    5.4.1 Sources
    5.4.2 Sources Not Used
    5.4.3 Forecast Assumptions and Methods
    5.5 Epidemiological Forecast for PD (2016-2026)
    5.5.1 Diagnosed Prevalent Cases of PD
    5.5.2 Age-Specific Diagnosed Prevalent Cases of PD
    5.5.3 Sex-Specific Diagnosed Prevalent Cases of PD
    5.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging
    5.6 Discussion
    5.6.1 Epidemiological Forecast Insight
    5.6.2 Limitations of the Analysis
    5.6.3 Strengths of the Analysis
    6 Disease Management
    6.1 Diagnosis and Treatment Overview
    6.2 US
    6.3 5EU
    6.4 Japan
    7 Competitive Assessment
    7.1 Overview
    8 Unmet Needs and Opportunity Assessment
    8.1 Overview
    8.2 Treatment of Motor Complications - Dyskinesia and OFF Episodes
    8.3 Treatment of Non-motor Complications and Dementia
    8.4 Neuroprotective/Disease-Modifying Agents
    8.5 Improved Drug Formulations
    9 Pipeline Assessment
    9.1 Overview
    9.2 Promising Drugs in Clinical Development
    10 Current and Future Players
    10.1 Overview
    10.2 Trends in Corporate Strategy
    10.3 AbbVie
    10.4 Roche
    10.5 Orion Pharma
    10.6 Impax Pharmaceuticals
    10.7 Acorda Therapeutics
    10.8 Adamas Pharmaceuticals
    10.9 UCB
    10.10 Kyowa Hakko Kirin
    10.11 Other Players
    11 Market Outlook
    11.1 Global Markets
    11.1.1 Forecast
    11.1.2 Drivers and Barriers - Global Issues
    11.2 US
    11.2.1 Forecast
    11.2.2 Key Events
    11.2.3 Drivers and Barriers
    11.3 5EU
    11.3.1 Forecast
    11.3.2 Key Events
    11.3.3 Drivers and Barriers
    11.4 Japan
    11.4.1 Forecast
    11.4.2 Key Events
    11.4.3 Drivers and Barriers
    12 Appendix
    12.1 Bibliography
    12.2 Abbreviations
    12.3 Methodology
    12.3.1 Forecasting Methodology
    12.3.2 Diagnosed Patients
    12.3.3 Percent Drug-Treated Patients
    12.3.4 Drugs Included in Each Therapeutic Class
    12.3.5 Launch and Patent Expiry Dates
    12.3.6 General Pricing Assumptions
    12.3.7 Individual Drug Assumptions
    12.3.8 Generic Erosion
    12.3.9 Pricing of Pipeline Agents
    12.4 Primary Research - KOLs [and Payers] Interviewed for This Report
    12.4.1 KOLs
    12.4.2 Payers
    12.5 Primary Research - Prescriber Survey
    12.6 About the Authors
    12.6.1 Analyst
    12.6.2 Therapy Area Director
    12.6.3 Epidemiologist
    12.6.4 Managing Epidemiologist
    12.6.5 Global Director of Therapy Analysis and Epidemiology
    12.6.6 Global Head and EVP of Healthcare Operations and Strategy
    12.7 About GlobalData
    12.8 Contact Us
    12.9 Disclaimer
    1.1 List of Tables
    Table 1: Parkinson’s Disease: Key Metrics in the 7MM
    Table 2: Risk Factors and Comorbidities for PD
    Table 3: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages ≥18 Years, N, 2016
    Table 4: Treatment Guidelines for PD
    Table 5: Country Profile - US
    Table 6: Country Profile - 5EU
    Table 7: Country Profile - Japan
    Table 8: Leading Treatments for Parkinson’s Disease, 2016
    Table 9: Comparison of Therapeutic Classes in Development for Parkinson’s Disease, 2016-2026
    Table 10: AbbVie’s Disease Portfolio Assessment, 2018
    Table 11: Roche’s Disease Portfolio Assessment, 2018
    Table 12: Orion Pharma’s Disease Portfolio Assessment, 2018
    Table 13: Impax Pharmaceuticals’ Disease Portfolio Assessment, 2018
    Table 14: Acorda Therapeutics’ Disease Portfolio Assessment, 2018
    Table 15: Adamas Pharmaceuticals’ Disease Portfolio Assessment, 2018
    Table 16: UCB’s Disease Portfolio Assessment, 2018
    Table 17: Kyowa Hakko Kirin’s Disease Portfolio Assessment, 2018
    Table 18: Parkinson’s Disease Market - Global Drivers and Barriers, 2016-2026
    Table 19: Key Events Impacting Sales for Parkinson’s Disease in the US, 2016-2026
    Table 20: Parkinson’s Disease Market - Drivers and Barriers in the US, 2016-2026
    Table 21: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2016-2026
    Table 22: Parkinson’s Disease Market - Drivers and Barriers in the 5EU, 2016-2026
    Table 23: Key Events Impacting Sales for Parkinson’s Disease in Japan, 2016-2026
    Table 24: Parkinson’s Disease Market - Global Drivers and Barriers in Japan, 2016-2026
    Table 25: Key Projected Launch Dates for Parkinson’s disease
    Table 26: Key Historical and Projected Patent Expiry Dates for Parkinson’s Disease
    Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
    1.2 List of Figures
    Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026
    Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
    Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
    Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages ≥18 Years, 2016
    Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016-2026
    Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of PD Clinical Staging, 2016-2026
    Figure 7: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, ≥18 Years, N, 2016
    Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016
    Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016
    Figure 10: Treatment Algorithm for Parkinson’s Patients
    Figure 11: Unmet Needs and Opportunities in Parkinson’s Disease
    Figure 12: Pharmacokinetics of Levodopa
    Figure 13: Overview of the Development Pipeline in Parkinson’s Disease
    Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period
    Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
    Figure 16: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
    Figure 17: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026
    Figure 18: Sales Forecast by Class for Parkinson’s Disease in the US in 2016 and 2026
    Figure 19: Country Breakdown for Parkinson’s Disease Sales in the 5EU in 2016 and 2026
    Figure 20: Sales Forecast by Class for Parkinson’s Disease in Japan in 2016 and 2026

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report